<h4>Background</h4>Monoclonal antibodies targeting vascular endothelial growth factor (VEGF), such as bevacizumab, are administered intravitreally for the treatment of wet or exudative age-related macular degeneration (ARMD). This evidence concerns the gene VEGFA and age-related macular degeneration.